Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma

doi:10.3390/cells13221823

科研成果详情

题名	Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma
作者	Kamara, Saidu; Wen, He; Guo, Yanru; Liu, Ying; Liu, Lei; Du, Wangqi; Chen, Jun; Zhu, Shanli; Zhang, Lifang
发表日期	2024-11
发表期刊	CELLS 影响因子和分区
语种	英语
原始文献类型	Article
关键词	affibody molecules nasopharyngeal carcinoma Axl EGFR targeted therapy
其他关键词	GROWTH-FACTOR RECEPTOR ; SMALL-MOLECULE INHIBITOR ; ANTIBODIES ; KINASE ; PEMBROLIZUMAB ; IPILIMUMAB ; EXPRESSION ; SURVIVAL ; EFFICACY ; INVASION
摘要	Nasopharyngeal carcinoma (NPC) is a tumor of the head and neck, with a higher incidence in southern China and Southeast Asia. Radiotherapy and chemotherapy are the main treatments; however, metastasis and recurrence remain the main causes of treatment failure. Further, the majority of patients are diagnosed in the late stage due to lack of tumor-specific biomarker for early diagnosis. Therefore, an effective treatment and early detection can improve the outcome of patient with NPC. Axl and EGFR are co-expressed in NPC tissues and play key roles in tumor proliferation, migration, and invasion, which are often correlated with poor prognosis and therapy resistance. In this study, we generated a novel bispecific affibody (Z239-1907) for the dual targeting and inhibition of Axl and EGFR expression in NPC-positive cells both in vitro and in vivo. The in vitro experiments demonstrated that Z239-1907 had more pronounced antitumor effects than either modality alone (ZAXL239 or ZEGFR1907) in NPC-positive cells. Further, mice bearing NPC-positive tumors showed significant inhibition in tumor growth after treatment with Z239-1907 compared to ZAXL239 and ZEGFR1907. The in vivo tumor targeting ability and imaging also showed that Z239-1907 specifically and selectively targeted NPC xenograft mice models and accumulate at tumor site as early as 30 min and disappeared within 24 h post-injection. Collectively, these results suggest that Z239-1907 dual-target affibody is a promising therapeutic agent and a molecular imaging probe for early diagnosis in NPC.
资助项目	National Nature Science Foundation of China; [81972550]
出版者	MDPI
ISSN	2073-4409
EISSN	2073-4409
卷号	13 期号:22
DOI	10.3390/cells13221823
页数	18
WOS类目	Cell Biology
WOS研究方向	Cell Biology
WOS记录号	WOS:001364093100001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	39594573
SCOPUSEID	2-s2.0-85210450855
通讯作者地址	[Zhang, Lifang]Wenzhou Med Univ, Inst Mol Virol & Immunol, Sch Basic Med Sci, Dept Microbiol & Immunol, Wenzhou 325035, Peoples R China.
Scopus学科分类	Biochemistry, Genetics and Molecular Biology (all)
SCOPUS_ID	SCOPUS_ID:85210450855
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/223523
专题	基础医学院（机能实验教学中心）_病原生物学与免疫学系
通讯作者	Zhang, Lifang
作者单位	Wenzhou Med Univ, Inst Mol Virol & Immunol, Sch Basic Med Sci, Dept Microbiol & Immunol, Wenzhou 325035, Peoples R China
第一作者单位	基础医学院（机能实验教学中心）_病原生物学与免疫学系
通讯作者单位	基础医学院（机能实验教学中心）_病原生物学与免疫学系
第一作者的第一单位	基础医学院（机能实验教学中心）_病原生物学与免疫学系
推荐引用方式 GB/T 7714	Kamara, Saidu,Wen, He,Guo, Yanru,et al. Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma[J]. CELLS,2024,13(22).
APA	Kamara, Saidu., Wen, He., Guo, Yanru., Liu, Ying., Liu, Lei., ... & Zhang, Lifang. (2024). Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma. CELLS, 13(22).
MLA	Kamara, Saidu,et al."Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma".CELLS 13.22(2024).